-
How Damaged CNS Myelin Remodels Before Loss
2026-09-11
Arafa et al. show that myelin swelling is an early, dynamic response to central nervous system damage and does not inevitably result in sheath loss. Across zebrafish, rodent, and human tissue, the study identifies neuronal activity as a modifiable factor that can worsen swelling, while also revealing a potential window for preserving or repairing compromised myelin.
-
Primidone: A Target-Aware Translational Framework
2026-09-10
Primidone (Mysoline) can serve as more than a repurposed antiepileptic: it is a target-aware probe spanning TRPM3, RIPK1, and translational biomarkers. This guide connects molecular assay design with ALS evidence while clarifying exposure, selectivity, and disease-model limitations.
-
DMH1: An ALK2 Inhibitor for Organoid Assays
2026-09-10
DMH1 is an ALK2 inhibitor that can serve as a pathway-resolved probe in pancreatic ductal organoids and NSCLC models. This article explains how to separate organoid formation, lineage composition, and cancer phenotypes when interpreting BMP pathway perturbation.
-
2-Hydroxypropyl-β-cyclodextrin Protocol Guide
2026-09-09
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide used to screen and improve the aqueous handling of poorly soluble hydrophobic compounds, particularly molecules with aromatic or phenyl groups. This dossier-based guide supports pharmaceutical and biochemical formulation workflows, but increased solubility should not be interpreted as proof of therapeutic efficacy, bioavailability, or suitability outside validated applications.
-
Methylprednisolone: Inflammation and Bone Models
2026-09-09
Methylprednisolone is a synthetic glucocorticoid receptor agonist used to interrogate cytokine control and glucocorticoid-associated skeletal injury. Its reported inhibition of TNF-alpha, modulation of NF-kappaB signaling, and defined rat-model parameters support reproducible research, but they do not establish clinical efficacy for bone preservation.
-
MALAT1–miR-125b–STAT3 Axis in Sepsis
2026-09-08
The reference study identifies a MALAT1–miR-125b–STAT3 regulatory axis that increases procalcitonin expression in sepsis-associated models. Its combination of clinical samples, LPS-stimulated U937 cells, RNA localization, interaction assays, and protein measurements provides a mechanistic framework for interpreting how a diagnostic biomarker may be regulated, while leaving clinical validation and in vivo causality unresolved.
-
Light-Inducible RNA Release for Regulated Gene Therapy
2026-09-08
The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic gene expression at the translation stage. Its compatibility with AAV delivery, light-sensitive cell systems, and tissue-accessible illumination suggests a practical route toward reversible gene therapies for metabolic and retinal disorders.
-
PPM-18: A Mechanistic Lens on Bone Inflammation
2026-09-07
PPM-18 is an NF-κB-linked iNOS expression inhibitor that can help researchers distinguish inflammatory transcription from downstream nitric oxide effects. This article develops a cautious, cross-domain framework for applying its mechanism to osteoimmune assay design without overstating evidence from sepsis or bone models.
-
CD38 CAR Binder Structure and Affinity Tuning
2026-09-05
Cheng and colleagues dissect how two CD38-targeting CAR binders engage distinct antigen surfaces and couple binding geometry to enzymatic inhibition. The study shows that rational affinity attenuation of 028 can reduce CAR-T fratricide while preserving antitumor cytotoxicity, offering a structure-guided framework for safer CD38-directed therapies.
-
Bacillus Media Shape γ-Glutamyl Peptide Production
2026-09-05
A December 2024 Food Bioscience study shows that both Bacillus strain selection and growth-medium composition shape γ-glutamyl peptide production, with hemoglobin hydrolysate generally supporting higher peptide concentrations than brain heart infusion broth. The findings also identify condition-specific glutathione formation and emphasize that medium composition may be a stronger process variable than strain identity.
-
Ivermectin for Reliable Cell Assay Workflows
2026-09-04
This scenario-driven guide shows how Ivermectin (SKU A2813) can support better-controlled viability, proliferation, and cytotoxicity workflows. It covers solvent compatibility, concentration calculations, assay optimization, interpretation limits, and evidence-based product selection for parasitology and exploratory oncology research.
-
PRINT: RNA-Mediated Transgene Insertion at Safe Harbors
2026-09-04
The reference study introduces PRINT, an RNA-only strategy that uses avian R2 retroelement proteins to insert transgenes at a multicopy human safe-harbor locus through target-primed reverse transcription. Its combination of site-directed integration, separate protein-encoding and template RNAs, and measurable activity in primary human cells addresses important limitations of CRISPR-mediated repair and viral delivery.
-
Ivermectin Workflows for Parasitology Research
2026-09-03
Build reproducible Ivermectin assays around solvent control, prompt solution use, orthogonal parasite readouts, and analytical verification. The workflow also shows how a recent pancreatic cancer study can improve assay design without overstating evidence for cross-domain applications.
-
BAPTA: Mapping Calcium-Driven Apoptosis
2026-09-03
A mechanistic guide to using BAPTA as a calcium chelator for testing the IP3R/Ca2+/STAT3 axis, strengthening apoptosis research, and translating environmental exposure findings into better experimental decisions.
-
TRAP-1 Reactivates p53Y220C Through Induced Proximity
2026-09-02
The bioRxiv preprint reports TRAP-1, a chemical inducer of proximity that assembles mutant p53Y220C with BRD4 to restore transcriptional activity. Its activity depends on ternary-complex formation, providing a mechanistic framework for reactivating selected tumor-suppressor mutants rather than merely stabilizing them.